Outsmarting cancer, together

Omico is a nationwide network of research and treatment centres that facilitates, supports and promotes clinical trials in genomic cancer medicine. Central to this is the use of molecular screening for the prevention and treatment of cancer.

Learn more

Our Vision

Omico will improve outcomes for Australians with cancer by accelerating the use of precision oncology as a research-led model of care, growing the clinical trials industry and modernising the Australian healthcare system.

Our Values

Innovation, Collaboration, and Hope

Our Mission

MoST Clinical Trials

MoST Substudies

Recent News

$185 million investment to fast-track treatments for rare and ‘untreatable’ cancers

The Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) will establish Australia as a medical manufacturing hub: building links from research through to the clinic; creating jobs; changing lives. A private public partnership to strengthen Australia’s position at the forefront of the cancer treatment revolution

Read more

APOS 2021 - DNA & Beyond - online event

Renowned experts discussing the future of genomic cancer medicine, developing new models for health care, data and machine learning. Join us for 4 sessions over 4 days to explore novel technologies, innovative therapies and a systems approach to managing cancer risk and providing healthcare. November Monday 22nd, Tuesday 23rd, Wednesday 24th and Thursday 25th November 2021; 5pm - 7pm AEST

Read more

Pancreatic cancer program

Cancer Institute NSW has awarded a Translational Program Grant to an impressive team of experienced laboratory and clinical researchers in pancreas cancer, coordinated by Chief Investigator Professor David Goldstein. The team is seeking to develop better targeted treatment options for pancreatic cancer – and ultimately, improve outcomes for people affected.

Read more
More news

Interested in knowing more?

Get in touch